Company search
Longest serving investment trust managers on lessons learned from investing through conflicts and crises
“Stay calm and keep things in perspective”.
Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Research
Please note that this research may have been paid for by the investment company. Any opinions and ratings are not endorsed by the AIC.
Kepler Trust Intelligence
11 March 2026
BIOG has soared as biotechnology has come back into favour.
Related articles
Commodities take gold in 2025 performance tables with 44% return
China comes in second, shrugging off trade war worries.
M&A activity drives momentum in biotech and healthcare
“The buying has not stopped” as excitement over weight loss drugs continues.
The 50 investment trusts that would have made you an ISA millionaire
Allianz Technology Trust is top performer with a return of nearly £3 million.
Related videos
Biotechnology & Healthcare: what are the challenges of investing in the sector?
Annabel Brodie-Smith asks managers about the challenges of investing in the Biotechnology & Healthcare sector.
Biotechnology & Healthcare: where are you finding opportunities?
A panel of Biotechnology & Healthcare managers discuss where they are currently finding opportunities.
Biotechnology & Healthcare: is the sector due a comeback?
Annabel Brodie-Smith, Brett Darke, Marek Poszepczynski and Geoff Hsu discuss whether Biotechnology & Healthcare is due a comeback.
Biotechnology & Healthcare: will the results of the US election make a difference for the sector?
Brett Darke, Marek Poszepczynski and Geoff Hsu on whether the results of the next US election will impact the Biotechnology & Healthcare sector.
Related industry news
Morning briefing: Biogen snaps up Apellis in boost BIOG and RTW; Baillie Gifford China Growth bounces back(...)
Biotech Growth (BIOG) and RTW Biotech Opportunities (RTW) have both benefited from Biogen’s announcement of a $5.6bn cash acquisition of Apellis Pharm...
How healthy is your portfolio?
Over six months have passed since Cherry Reynard wrote about the biotech and healthcare sector for us in this article – The biotech bust: a case study...
Morning briefing: RTW Biotech launches Yarrow Bioscience; Nippon Active sells its biggest holding; shrinking Bellevue Healthcare ploughs on with buybacks; plus AEET
RTW Biotech Opportunities (RTW) has invested $5.9m in the series A financing of Yarrow Bioscience, a new clinical-stage company it helped found to dev...
Trust Spot: Uranium fund takes breather as bids, wind-downs and buybacks keep investors on their toes
A look at October’s top risers and fallers reveals another busy month for investment companies. Best performing investment companies October’s biggest...
Investment company news brought to you by Citywire Financial Publishers Limited
and QuotedData by Marten & Co.
Data provided by Morningstar.
Company documents provided by FE fundinfo.
